Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
In Candida albicans , the ERG11 gene encodes lanosterol demethylase, the target of the azole antifungals. Mutations in ERG11 that result in an amino acid substitution alter the abilities of the azoles to bind to and inhibit Erg11, resulting in resistance. Although ERG11 mutations have been observed in clinical isolates, the specific contributions of individual ERG11 mutations to azole resistance in C. albicans have not been widely explored. We sequenced ERG11 in 63 fluconazole (FLC)-resistant clinical isolates. Fifty-five isolates carried at least one mutation in ERG11 , and we observed 26 distinct positions in which amino acid substitutions occurred. We mapped the 26 distinct variant positions in these alleles to four regions in the predicted structure for Erg11, including its predicted catalytic site, extended fungus-specific external loop, proximal surface, and proximal surface-to-heme region. In total, 31 distinct ERG11 alleles were recovered, with 10 ERG11 alleles containing a single amino acid substitution. We then characterized 19 distinct ERG11 alleles by introducing them into the wild-type azole-susceptible C. albicans SC5314 strain and testing them for susceptibilities to FLC, itraconazole (ITC), and voriconazole (VRC). The strains that were homozygous for the single amino acid substitutions Y132F, K143R, F145L, S405F, D446E, G448E, F449V, G450E, and G464S had a ≥4-fold increase in FLC MIC. The strains that were homozygous for several double amino acid substitutions had decreased azole susceptibilities beyond those conferred by any single amino acid substitution. These findings indicate that mutations in ERG11 are prevalent among azole-resistant clinical isolates and that most mutations result in appreciable changes in FLC and VRC susceptibilities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, in Candida auris, ERG11 polymorphisms as well as an increased number of ERG11 gene copies are thought to be responsible for its largely intrinsic azole resistance37–40”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [38]
In the citing paper
“Aneuploidy can alter fluconazole tolerance in C. albicans drug38,51.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [38]
In the citing paper
“Aneuploidy and/or loss of heteroresistance are rapidly acquired genome changes that can result in increased tolerance. and are likely to affect one or several genes that alter tolerance level.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [38]
In the citing paper
“Frequently reported in association with triazole resistance in both yeast and molds, mutations in sterol-demethylase have been observed to have variable and agent specific effects on the MICs of triazole antifungals, potentially as a result of agent-specific stabilizing interactions with sterol-demethylase residues (4, 5).”
From Delineation of the Direct Contribution of Candida auris ERG11 Mutations to Clinical Triazole Resistance (2021) · cites this paper as [5]
In the citing paper
“In both Candida albicans and Aspergillus fumigatus, the mutation encoding a tyrosine to phenylalanine amino acid substitution at a specific residue localized to the sterol-demethylase catalytic domain (Y132F in C. albicans CaERG11 and Y121F in A. fumigatus Afcyp51A) confers increased resistance to all triazoles except for posaconazole (4–7).”
From Delineation of the Direct Contribution of Candida auris ERG11 Mutations to Clinical Triazole Resistance (2021) · cites this paper as [5]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins
MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., et al. (1998) · The Journal of Physical Chemistry B · doi:10.1021/jp973084f · Cited by 14,311
Amino acid substitution matrices from protein blocks.
Henikoff, S., & Henikoff, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10915 · Cited by 6,218
Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94
Halgren, T. A. (1996) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(199604)17:5/6<490::aid-jcc1>3.0.co;2-p · Cited by 5,306
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
The SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742
Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Cytochrome P450 and the Individuality of Species
Nelson, D. R. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1352 · Cited by 591
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Research works printed but not linked: 1
- Sanglard D, Bille J. 2002. Action of and resistance to antifungal agents, p 370. In Calderone RA (ed), Candida and candidiasis. American Society for Microbiology, Washington, DC.
Cited by
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“Recently, 63 fluconazole-resistant C. albicans clinical isolates were examined for mutations within their ERG11 alleles, and 55 were found to carry at least one mutation that resulted in amino acid substitutions, with nine such predicted amino acid substitutions being novel (Flowers et al., 2015).”
BackgroundSelf-citationAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Chowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Candida auris : The recent emergence of a multidrug-resistant fungal pathogen
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S. (2019) · Medical Mycology · doi:10.1093/mmy/myy054 · Cited by 421
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
An Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Candida auris and multidrug resistance: Defining the new normal
Lockhart, S. R. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103243 · Cited by 205
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
Self-citationUpdate on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01427-18 · Cited by 165
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
“Mutations in ERG11 are frequent among azole-resistant clinical fungal strains [103].”
BackgroundA comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise
Howard, K. C., Dennis, E. K., Watt, D. S., & Garneau-Tsodikova, S. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00556k · Cited by 140
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Sabherwal, M., Tyndall, J. D. A., & Monk, B. C. (2016) · Scientific Reports · doi:10.1038/srep26213 · Cited by 117
Szekely, A., Borman, A. M., & Johnson, E. M. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.02055-18 · Cited by 125
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Morschhäuser, J. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5628-4 · Cited by 118
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 117
Keniya, M. V., Sabherwal, M., Wilson, R. K., Woods, M. A., Sagatova, A. A., Tyndall, J. D. A., & Monk, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01134-18 · Cited by 115
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi
Hokken, M., Zwaan, B. J., Melchers, W. J. G., & Verweij, P. E. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103254 · Cited by 110
Nishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Self-citationDrug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Jensen, R. H., Astvad, K. M. T., Silva, L. V., Sanglard, D., Jørgensen, R., Nielsen, K. F., Mathiasen, E. G., Doroudian, G., Perlin, D. S., & Arendrup, M. C. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv140 · Cited by 95
Berkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01358-15 · Cited by 95
Self-citationRosam, K., Monk, B. C., & Lackner, M. (2020) · Journal of Fungi · doi:10.3390/jof7010001 · Cited by 95
Identification of Mycoses in Developing Countries
Arastehfar, A., Wickes, B. L., Ilkit, M., Pincus, D. H., Daneshnia, F., Pan, W., Fang, W., & Boekhout, T. (2019) · Journal of Fungi · doi:10.3390/jof5040090 · Cited by 63
Fekkar, A., Blaize, M., Bouglé, A., Normand, A.-C., Raoelina, A., Kornblum, D., Kamus, L., Piarroux, R., & Imbert, S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02036-20 · Cited by 85
Spettel, K., Barousch, W., Makristathis, A., Zeller, I., Nehr, M., Selitsch, B., Lackner, M., Rath, P.-M., Steinmann, J., & Willinger, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210397 · Cited by 86
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Coping with Stress and the Emergence of Multidrug Resistance in Fungi
Shor, E., & Perlin, D. S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004668 · Cited by 71
Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens
Sharma, J., Rosiana, S., Razzaq, I., & Shapiro, R. S. (2019) · Journal of Fungi · doi:10.3390/jof5010017 · Cited by 65
A titanic drug resistance threat in Cryptococcus neoformans
Zafar, H., Altamirano, S., Ballou, E. R., & Nielsen, K. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.11.001 · Cited by 76
Espinel-Ingroff, A., Turnidge, J., Alastruey-Izquierdo, A., Botterel, F., Canton, E., Castro, C., Chen, Y.-C., Chen, Y., Chryssanthou, E., Dannaoui, E., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-18 · Cited by 72
Branco, J., Ola, M., Silva, R. M., Fonseca, E. S. S., Gomes, N. C., Martins-Cruz, C., Silva, A. P., Silva-Dias, A., Pina‐Vaz, C., Erraught, C., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.002 · Cited by 75
Iyer, K. R., Camara, K., Daniel-Ivad, M., Trilles, R., Pimentel-Elardo, S. M., Fossen, J. L., Marchillo, K., Liu, Z., Singh, S., Muñoz, J. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20183-3 · Cited by 72
Assress, H. A., Selvarajan, R., Nyoni, H. H., Mamba, B. B., & Msagati, T. A. M. (2021) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-021-09594-w · Cited by 73
Real-Time Imaging of the Azole Class of Antifungal Drugs in Live Candida Cells
Benhamou, R. I., Bibi, M., Steinbuch, K. B., Engel, H., Levin, M., Roichman, Y., Berman, J., & Fridman, M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00339 · Cited by 71
Rybak, J. M., Sharma, C., Doorley, L. A., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01585-21 · Cited by 69
“albicans, where a wide repertoire of mutations have been observed among fluconazole-resistant isolates, the majority of which are found within three hot spot regions corresponding to amino acids 105 to 165, 266 to 287, and 405 to 488 (4, 5).”
InfluentialSelf-citationMultidrug transporters of Candida species in clinical azole resistance
Prasad, R., Nair, R., & Banerjee, A. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103252 · Cited by 57
Ergosterol Biosynthesis and Regulation Impact the Antifungal Resistance and Virulence of Candida spp
Eliaš, D., Tóth Hervay, N., & Gbelská, Y. (2024) · Stresses · doi:10.3390/stresses4040041 · Cited by 63
“Changes in ergosterol biosynthesis are frequently observed in clinical isolates of Candida spp. that are resistant to antifungal azoles or polyenes [58,59,122–124].”
Salazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
Azole resistance in Candida auris: mechanisms and combinatorial therapy
Jangir, P., Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Apmis · doi:10.1111/apm.13336 · Cited by 61
Fernandes, C. M., & Poeta, M. D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1792288 · Cited by 61
Warrilow, A. G., Nishimoto, A. T., Parker, J. E., Price, C. L., Flowers, S. A., Kelly, D. E., Rogers, P. D., & Kelly, S. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02586-18 · Cited by 60
“Strains expressing seven single mutations (Y132F, K143R, F145L, S405F, G448E, G450E, G464S) and three double mutations (Y132F K143R, Y132F F145L, D278N G464S) were selected from a previous study (36).”
Self-citationBédard, C., Gagnon‐Arsenault, I., Boisvert, J., Plante, S., Dubé, A. K., Pageau, A., Fijarczyk, A., Sharma, J., Maroc, L., Shapiro, R. S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01819-2 · Cited by 56
Mane, A., Vidhate, P., Kusro, C., Waman, V., Saxena, V., Kulkarni‐Kale, U., & Risbud, A. (2016) · Mycoses · doi:10.1111/myc.12439 · Cited by 41
Asadzadeh, M., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2016.0336 · Cited by 53
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Self-citationGündel, S. D. S., de Godoi, S. N., Santos, R. C. V., da Silva, J. T., Leite, L. B. D. M., Amaral, A. C., & Ourique, A. F. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101762 · Cited by 52
Minimum Inhibitory Concentration (MIC) Assay for Antifungal Drugs
Xie, J., Singh-Babak, S., & Cowen, L. (2012) · BIO-PROTOCOL · doi:10.21769/bioprotoc.252 · Cited by 46
Xisto, M. I. D. S., Caramalho, R. D. F., Rocha, D. A. S., Ferreira-Pereira, A., Sartori, B., Barreto-Bergter, E., Junqueira, M. L., Lass-Flörl, C., & Lackner, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw558 · Cited by 41
Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 45
Yassin, M. T., Elgorban, A. M., Al-Askar, A. A., Sholkamy, E. N., Ameén, F., & Maniah, K. (2023) · Micromachines · doi:10.3390/mi14010209 · Cited by 50
Ceballos-Garzón, A., Peñuela, A., Valderrama, S., Vargas‐Casanova, Y., Ariza, B., & Parra‐Giraldo, C. M. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1136217 · Cited by 49
Li, Q., Tsai, H., Mandal, A., Walker, B., Noble, J., Fukuda, Y., & Bennett, J. E. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8716 · Cited by 48
Popp, C., Ramírez-Zavala, B., Schwanfelder, S., Krüger, I., & Morschhäuser, J. (2019) · mBio · doi:10.1128/mbio.02740-18 · Cited by 42
Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161
Monk, B. C., Keniya, M. V., Sabherwal, M., Wilson, R. K., Graham, D. O., Hassan, H. F., Chen, D., & Tyndall, J. D. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02114-18 · Cited by 47
Soman, R., Raghav, D., Sujatha, S., Rathinasamy, K., & Arunkumar, C. (2015) · RSC Advances · doi:10.1039/c5ra09343k · Cited by 46
Novel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida species
Silva, D. B. D. S., Rodrigues, L. M. C., Almeida, A. A. D., Oliveira, K. M. P. D., & Grisolia/, A. B. (2016) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150400 · Cited by 42
“…acids (aa) 105- 165, 266-287, and-488 from Candida albicans, those regions were associated which Candida species resistant to azoles (Marichal et al. 1999, Perea et al. 2001, Chau et al. 2004, Vandeputte et al. 2005, Morio et al. 2010, Flowers et al. 2015, Grossman et al. 2015, Tan et al. 2015).”
BackgroundGenomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta
Park, M., Cho, Y., Lee, Y. W., & Jung, W. H. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00191 · Cited by 41
Candida auris:a fungus with identity crisis
Vila, T. V. M., Sultan, A. S., Montelongo‐Jauregui, D., & Jabra‐Rizk, M. A. (2020) · Pathogens and Disease · doi:10.1093/femspd/ftaa034 · Cited by 41
Aspergillus fumigatus Cross-Resistance between Clinical and Demethylase Inhibitor Azole Drugs
Garcia‐Rubio, R., González-Jiménez, I., Lucio, J. L., & Mellado, E. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.02539-20 · Cited by 41
Feng, Y., Lu, H., Whiteway, M., & Jiang, Y. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.019 · Cited by 40
Distorted Gold(I)–Phosphine Complexes as Antifungal Agents
Dennis, E. K., Kim, J. H., Parkin, S., Awuah, S. G., & Garneau‐Tsodikova, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01436 · Cited by 39
de Oliveira, J. S., Pereira, V. S., Castelo‐Branco, D. D. S. C. M., Cordeiro, R. D. A., Sidrim, J. J. C., Brilhante, R. S. N., & Rocha, M. F. G. (2020) · Canadian Journal of Microbiology · doi:10.1139/cjm-2019-0531 · Cited by 39
The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections
Boahen, A., Than, L. T. L., Loke, Y.-L., & Chew, S. Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.787119 · Cited by 39
Rodríguez-Castaño, G. P., Rosenau, F., Ständker, L., & Firacative, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030789 · Cited by 38
Monk, B. C., & Keniya, M. V. (2021) · Journal of Fungi · doi:10.3390/jof7020067 · Cited by 37
Current and promising pharmacotherapeutic options for candidiasis
Scorzoni, L., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E. E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873951 · Cited by 36
Break, T. J., Desai, J. V., Healey, K. R., Natarajan, M., Ferré, E. M. N., Henderson, C. M., Zelazny, A. M., Siebenlist, U. K., Yates, C. M., Cohen, O. J., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky170 · Cited by 36
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Kukurudz, R. J., Chapel, M., Wonitowy, Q., Adamu Bukari, A.-R., Sidney, B., Sierhuis, R., & Gerstein, A. C. (2022) · G3 · doi:10.1093/g3journal/jkac156 · Cited by 35
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Hetta, H. F., Melhem, T., Aljohani, H. M., Salama, A., Ahmed, R., Elfadil, H., Alanazi, F. E., Ramadan, Y. N., Battah, B., Rottura, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030364 · Cited by 35
Vu, B. G., & Moye-Rowley, S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02098-21 · Cited by 33
Derkacz, D., Bernat, P., & Krasowska, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031631 · Cited by 33
Odiba, A. S., Durojaye, O. A., Ezeonu, I. M., Mgbeahuruike, A. C., & Nwanguma, B. C. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s360973 · Cited by 33
Sagatova, A. A., Keniya, M. V., Tyndall, J. D. A., & Monk, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02242-17 · Cited by 33
Després, P. C., Cisneros, A. F., Alexander, E. M. M., Sonigara, R., Gagné-Thivierge, C., Dubé, A. K., & Landry, C. R. (2022) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01846-4 · Cited by 32
Analysis of Cyp51 protein sequences shows 4 major Cyp51 gene family groups across fungi
Celia-Sanchez, B. N., Mangum, B., Brewer, M. T., & Momany, M. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac249 · Cited by 32
Uncovering New Mutations Conferring Azole Resistance in the Aspergillus fumigatus cyp51A Gene
Chen, P., Liu, M., Zeng, Q., Zhang, Z., Liu, W., Sang, H., & Lü, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03127 · Cited by 32
Scott, N. A., Sharpe, L. J., Capell-Hattam, I. M., Gullo, S. J., Luu, W., & Brown, A. J. (2020) · Biochemical Journal · doi:10.1042/bcj20190647 · Cited by 31
Importation, Mitigation, and Genomic Epidemiology of Candida auris at a Large Teaching Hospital
Lesho, E. P., Bronstein, M. Z., McGann, P., Stam, J., Kwak, Y., Maybank, R., McNamara, J., Callahan, M., Campbell, J., Hinkle, M. K., et al. (2018) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2017.231 · Cited by 29
Binjubair, F. A., Parker, J. E., Warrilow, A. G. S., Puri, K., Braidley, P. J., Tatar, E., Kelly, S. L., Kelly, D. E., & Simons, C. (2020) · ChemMedChem · doi:10.1002/cmdc.202000250 · Cited by 31
Baker, K. M., Hoda, S., Saha, D., Gregor, J. B., Georgescu, L., Serratore, N. D., Zhang, Y., Cheng, L., Lanman, N. A., & Briggs, S. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02250-21 · Cited by 30
Antifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
Williamson, B., Wilk, A. S., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Sawh, I., Cancino-Prado, G., Gardam, D., Heath, C. H., Govender, N. P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-21 · Cited by 30
Pandey, N., Tripathi, M., Gupta, M. K., & Tilak, R. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.02.010 · Cited by 30
Shao, J., Cui, Y., Zhang, M.-X., Wang, T., Wu, D., & Wang, C. (2016) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1237977 · Cited by 29
CoERG11 A395T mutation confers azole resistance in Candida orthopsilosis clinical isolates
Rizzato, C., Poma, N. V., Zoppo, M., Posteraro, B., Mello, E., Bottai, D., Lupetti, A., Sanguinetti, M., & Tavanti, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky122 · Cited by 29
Biswas, C., Wang, Q., van Hal, S. J., Eyre, D. W., Hudson, B. J., Halliday, C. L., Mazsewska, K., Gordon, A. K., Lee, A. S., Irinyi, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa158 · Cited by 29
Morio, F., Lombardi, L., Binder, U., Logé, C., Robert, E., Grässle, D., Bodin, M., Lass‐Flörl, C., Butler, G., & Pape, P. L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz204 · Cited by 29
Metadata
- Authors
- Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D.
- Affiliations
- University of Tennessee Health Science Center (US)
- University of Illinois Urbana-Champaign (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-01
- Volume
- 59
- Issue
- 1
- Pages
- 450-460
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC4291385
- OpenAlex
- W2151649073
- Cited by
- 294
- References
- 46
- Citations by year
- 2026: 25 · 2025: 33 · 2024: 31 · 2023: 39 · 2022: 31 · 2021: 29 · 2020: 33 · 2019: 26 · 2018: 15 · 2017: 17 · 2016: 8 · 2015: 7
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida albicans, ERG11, azole resistance, fluconazole resistance, itraconazole, voriconazole, amino acid substitutions, clinical isolates, double mutations, antifungal susceptibility, drug target mutations
- MeSH terms
- Antifungal Agents, Azoles, Candida albicans, Candidiasis, Humans, Microbial Sensitivity Tests, Molecular Sequence Data, Fluconazole, Itraconazole, Amino Acid Substitution, Catalytic Domain, Drug Resistance, Fungal, Sterol 14-Demethylase, 14-alpha Demethylase Inhibitors, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.